CN105980859B - 针对溶酶体酶的底物清除测定 - Google Patents

针对溶酶体酶的底物清除测定 Download PDF

Info

Publication number
CN105980859B
CN105980859B CN201580008136.XA CN201580008136A CN105980859B CN 105980859 B CN105980859 B CN 105980859B CN 201580008136 A CN201580008136 A CN 201580008136A CN 105980859 B CN105980859 B CN 105980859B
Authority
CN
China
Prior art keywords
lysosomal enzyme
cells
sample
lysosomal
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580008136.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105980859A (zh
Inventor
V·克哈杰拉尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of CN105980859A publication Critical patent/CN105980859A/zh
Application granted granted Critical
Publication of CN105980859B publication Critical patent/CN105980859B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7057—(Intracellular) signaling and trafficking pathways
    • G01N2800/7066—Metabolic pathways

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201580008136.XA 2014-02-18 2015-02-18 针对溶酶体酶的底物清除测定 Active CN105980859B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461941365P 2014-02-18 2014-02-18
US61/941,365 2014-02-18
PCT/US2015/016394 WO2015126953A1 (en) 2014-02-18 2015-02-18 Substrate clearance assays for lysosomal enzymes

Publications (2)

Publication Number Publication Date
CN105980859A CN105980859A (zh) 2016-09-28
CN105980859B true CN105980859B (zh) 2018-10-19

Family

ID=52649105

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580008136.XA Active CN105980859B (zh) 2014-02-18 2015-02-18 针对溶酶体酶的底物清除测定

Country Status (10)

Country Link
US (1) US11187697B2 (enExample)
EP (1) EP3108258B1 (enExample)
JP (1) JP6684715B2 (enExample)
CN (1) CN105980859B (enExample)
AU (1) AU2015219097B2 (enExample)
BR (1) BR112016018978B1 (enExample)
CA (1) CA2938498A1 (enExample)
EA (1) EA201691393A1 (enExample)
MX (1) MX373640B (enExample)
WO (1) WO2015126953A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11396499B2 (en) 2018-12-12 2022-07-26 University Of Washington Lysosomal acid lipase assay

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018539A2 (en) * 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
WO2005059163A2 (en) * 2003-12-15 2005-06-30 Applera Corporation Methods, compositions, and kits for analysis of enzyme activity in cells
CN101730746A (zh) * 2007-07-06 2010-06-09 帕普斯特许可有限两合公司 检测蛋白酶的活力
CN102027110A (zh) * 2008-01-18 2011-04-20 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
WO2011100392A2 (en) * 2010-02-10 2011-08-18 Nova Southeastern University Methionine gamma lyase-2-aminobutyrate (megl-2abd) and therapeutic uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0650396T3 (da) * 1993-05-17 1998-09-14 Amersham Int Plc Udstyr og fremgangsmåde til måling af celluære biokemiske processer.
DK1007971T3 (da) * 1997-08-18 2004-12-06 Amersham Plc Scintillationsproximitetstest

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018539A2 (en) * 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
WO2005059163A2 (en) * 2003-12-15 2005-06-30 Applera Corporation Methods, compositions, and kits for analysis of enzyme activity in cells
CN101730746A (zh) * 2007-07-06 2010-06-09 帕普斯特许可有限两合公司 检测蛋白酶的活力
CN102027110A (zh) * 2008-01-18 2011-04-20 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
WO2011100392A2 (en) * 2010-02-10 2011-08-18 Nova Southeastern University Methionine gamma lyase-2-aminobutyrate (megl-2abd) and therapeutic uses thereof

Also Published As

Publication number Publication date
US11187697B2 (en) 2021-11-30
EP3108258A1 (en) 2016-12-28
WO2015126953A1 (en) 2015-08-27
CN105980859A (zh) 2016-09-28
JP2017506508A (ja) 2017-03-09
MX2016010719A (es) 2016-11-23
BR112016018978A2 (enExample) 2017-08-15
EP3108258B1 (en) 2019-12-04
AU2015219097A1 (en) 2016-08-18
AU2015219097B2 (en) 2021-02-11
CA2938498A1 (en) 2015-08-27
MX373640B (es) 2020-05-04
EA201691393A1 (ru) 2016-12-30
US20170219566A1 (en) 2017-08-03
JP6684715B2 (ja) 2020-04-22
BR112016018978B1 (pt) 2024-03-12

Similar Documents

Publication Publication Date Title
Ravi et al. Human organotypic brain slice culture: a novel framework for environmental research in neuro-oncology
Griffin et al. MOR23 promotes muscle regeneration and regulates cell adhesion and migration
Denis et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets
CN101400697B (zh) 寻常鱼鳞病、特异反应性和其他病症的预防/治疗
Sohrabi et al. Microenvironmental stiffness induces metabolic reprogramming in glioblastoma
Gilbert et al. The response of human anulus fibrosus cells to cyclic tensile strain is frequency‐dependent and altered with disc degeneration
Hinek et al. Impaired elastic-fiber assembly by fibroblasts from patients with either Morquio B disease or infantile GM1-gangliosidosis is linked to deficiency in the 67-kD spliced variant of β-galactosidase
Dai et al. Microfluidic disc-on-a-chip device for mouse intervertebral disc—pitching a next-generation research platform to study disc degeneration
EP2094310B1 (en) Marker genes for use in the identification of chondrocyte phenotypic stability and in the screening of factors influencing cartilage production
JP2014110799A (ja) 骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法
Frangini et al. Synthesis of Mitochondrial DNA Precursors during Myogenesis, an Analysis in Purified C2C12 Myotubes*[S]
Asnaghi et al. Biomarker signatures of quality for engineering nasal chondrocyte-derived cartilage
Pustovalova et al. High-LET proton irradiation significantly alters the clonogenic and tumorigenic potential of human breast cancer cell lines in vitro and in vivo
CN105980859B (zh) 针对溶酶体酶的底物清除测定
Mei et al. MIR‐203‐3p promotes senescence of mouse bone marrow mesenchymal stem cells via downregulation of PBK
WO2013101276A2 (en) Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway
Reihs et al. An Animal‐Free Patient‐Derived Tissue‐Mimetic Biochip Model of the Human Synovial Membrane for Human‐Relevant Osteoarthritis Research
US20060003311A1 (en) In vitro screening of cellular events using 3d cell culture systems
EP2667191B1 (en) Method for evaluation of regenerated cartilage
Kato et al. Protocol for gene knockdown using siRNA in primary cultured neonatal murine microglia
Krenning et al. Time-resolved single-cell sequencing identifies multiple waves of mRNA decay during mitotic exit
Ruiz-Velasco et al. Mavacamten improves energy balance in a pre-clinical model of RASopathy-associated hypertrophic cardiomyopathy
US20090305905A1 (en) Compositions and methods relating to characterization and therapeutic application of pristine stem cells
Griesbach In silico analysis of tissue mineralization and mechanoregulation in a FKBP10 osteogenesis imperfecta organotypic bone model
Yao et al. Biomimetic model for the identification of distinctive microenvironmental factors in glioblastoma radiosensitivity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210713

Address after: Osaka

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Patentee before: SHIRE HUMAN GENETIC THERAPIES, Inc.

TR01 Transfer of patent right